Patent · US Active

Inhibitors of the CD95 signaling pathway for treatment of MDS

US9540431B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignee

APOGENIX AG · DE

Inventors

Harald Fricke · Mannheim, DE
Michaela Fontenay · Paris, FR
Claudia KUNZ · Lustadt, DE

Key dates

Filing date	Jul 18, 2013
Grant date	Jan 10, 2017
Priority date	—
Expiry date	Jul 18, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/22
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.